


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395		A1	(11) International Publication Number: WO 98/33524
			(43) International Publication Date: 6 August 1998 (06.08.98)
(21) International Application Number: PCT/US98/00985 (22) International Filing Date: 29 January 1998 (29.01.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 08/794,740 3 February 1997 (03.02.97) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71)(72) Applicants and Inventors: BECKER, Kenneth, L. [US/US]; 1617 34th Street, N.W., Washington, DC 20007 (US). WHITE, Jon, C. [US/US]; 15 Newlands Street, Chevy Chase, MD 20815 (US). NYLEN, Eric, S. [US/US]; 6305 Herkis Court, Bethesda, MD 20817 (US). SNIDER, Richard, H., Jr. [US/US]; 16700 Dorchester Place, Upper Marlboro, MD 20772-3449 (US).			
(74) Agents: BAXTER, Stephen, G. et al.; Oblon, Spivak, McClelland, Maier & Neustadt, P.C., 4th floor, Crystal Square Five, 1755 Jefferson Davis Highway, Arlington, VA 22202 (US).			
(54) Title: METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME INCLUDING SEPSIS			
(57) Abstract Administration of an antibody reactive to procalcitonin and/or its components is effective for the treatment and/or prevention of systemic inflammatory response syndrome (SIRS) and sepsis.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION

METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING
THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME INCLUDING SEPSIS

BACKGROUND OF THE INVENTIONField of the Invention:

The present invention relates to a method for preventing and/or treating the clinical illness currently termed systemic inflammatory response syndrome (SIRS) including sepsis (SIRS/sepsis). The present invention also relates to pharmaceutical compositions useful for the prevention and/or treatment of SIRS/sepsis.

Discussion of the Background:

Inflammation, a component of host protection, is the composite, successive events in response to an injury that may be infectious or non-infectious. Inflammation involves a wide variety of physiologic, cellular and molecular events, including vasodilatation; increased vascular permeability; extravasation of plasma leading to interstitial edema; chemotaxis of neutrophils, macrophages and lymphocytes; activation of complement; and stimulation of antibodies.

Important proximal mediators of this response include two inflammatory cytokines, interleukin-1 β (IL-1 β) and tumor necrosis factor alpha (TNF α) (Hamilton G, et al., Scand. J. Infect. Dis., 1992; 24:361; and Bone RC, Crit. Care Med. 1996; 24:163). They are produced primarily by macrophages, assist beneficially in the local inflammatory response, and act in conjunction with other cytokines, prostaglandins,

leukotrienes, complement, histamine, serotonin, substance P, and other mediators.

Bacterial infection and other potent stimuli often initiate a marked augmentation of pro-inflammatory cytokines that results in systemic inflammation (Burrell R, Circ. Shock, 1994; 43:137; and Bahrani S, et al., Prog. Clin. Biol. Res., 1995; 392:197). This condition is termed the "systemic inflammatory response syndrome" (SIRS). It may be self-limited or lead to a "multiple organ dysfunction syndrome" (MODS) (e.g., varying degrees of fever, hypoxemia, tachypnea, tachycardia, endothelial inflammation, myocardial insufficiency, hypoperfusion, altered mental status, vascular collapse, which may culminate in end-organ damage such as acute respiratory distress syndrome, coagulopathy, cardiac failure, renal failure, shock, and/or coma) (see: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, Crit. Care Med., 1992; 20:864; and Bone RC, JAMA, 1995; 273:155).

When SIRS is caused by infection, it is termed sepsis which, in turn, has progressively severe stages (severe sepsis, and septic shock). The diagnosis of sepsis does not obligate the demonstration of microorganisms, which may be presumed rather than demonstrated. Consequently, some authors subdivide the sepsis syndromes into "culture-positive" indicating that the causative microorganism(s) has(have) been identified, and "culture-negative" implying that the SIRS/sepsis is presumed to be caused by an infectious agent (see: Rangel-Fausto MS, et al., JAMA, 1995; 273:117).

SIRS/sepsis is a self-perpetuating condition. Depending on the severity of the condition, the mortality rate averages 20-70%.

In the United States, nearly one-half million cases occur yearly; it has been estimated to represent the 13th leading cause of death, and is the major proximate cause of mortality in intensive care units (Centers for Disease Control, MMWR, 1990; 39:31; and Lowry SF, Crit. Care Med., 1994; 22:S1-2).

Although the serum levels of certain proinflammatory cytokines tend to be higher with SIRS/sepsis, clinical trials have revealed a rather poor correlation between these levels and the degree of organ dysfunction, overall clinical course, or survival (Bone RC, Crit. Care Med. 1996; 24:163). Moreover, some cytokines may exist both in cell-associated and free forms, and only the latter are easily measured. Furthermore, because many cytokines have paracrine or autocrine functions, their levels may be elevated in local pools only and may not be detectable in the systemic circulation. Also, cytokines typically increase only transiently and may not be detected with a single serum sampling. Other rough correlates of sepsis include the acute-phase polypeptide, C-reactive protein, originating from the liver, and neopterin (Grabosch R, et al., Burns, 1992; 18-113), a heterocyclic metabolite produced by macrophages when they are stimulated by endotoxin or interferon-γ. Importantly, to date, there has been no reliable marker for the presence, the course, the response to therapy, or the

prognosis of SIRS/sepsis (Bone RC, Crit. Care Med. 1996; 24:163).

It has become apparent that infectious diseases and SIRS/sepsis (with or without known infection) are often characterized by varying degrees of hyperprocalcitonemia; indeed, serum procalcitonin (ProCT) and/or some of its components can reach enormous levels (Becker KL, et al., Anat. Rec., 1993; 236:136; Assicot M, et al., Lancet, 1993; 341:515; Becker KL, et al., "The hyperprocalcitonemia of severe infections," Endocrine Society, Washington, DC, June 1995; and Becker KL, et al., "Hyperprocalcitonemia as a clinical marker for systemic inflammation," ICAAC, New Orleans, LA, Sept. 16, 1996). Increased levels of ProCT and its components have been found in acute pulmonary illnesses, such as bacterial pneumonia or aspiration pneumonitis, that normalized with recovery. Patients with residual disease continued to have levels above normal (Becker KL, et al., The Endocrine Lung in Health and Disease, WB Saunders, Philadelphia, 1984; p. 277; and Nylen ES, et al., Am. J. Med. Sci. 1996; 312:12). Using specific antisera to ProCT, to the amino terminus of ProCT (nProCT), to calcitonin (CT), and to the calcitonin carboxyl peptide-I (CCP-I), in conjunction with HPLC and gel filtration techniques, it has been demonstrated that these patients have markedly increased serum levels of intact ProCT, nProCT, and usually the uncleaved CT:CCP-I peptide. However, mature CT usually remains normal or minimally elevated (Snider, R et al., "Characterization of the hyperprocalcitonemia of inflammatory/infectious disorders," Am. Fed. Clin. Res., New

Orleans, LA, Feb. 1, 1996; Becker, KL, et al., "The hyperprocalcitonemia of severe infections: Associated secretion of other constituents of the prohormone," Endocrine Society, Washington, DC, June 14-17, 1995).

Subsequently, in other infections (staphylococcus-induced toxic shock syndrome (Sperber SJ, et al., Rev. Inf. Dis., 1990; 12:736), bacterial meningitis (Assicot M, et al., Lancet, 1993; 341:515), melioidosis (Smith MD, et al., Clin. Infect. Dis., 1995; 20:641), acute falciparum malaria (Davis TME, et al., Trans. Roy. Soc. Trop. Med. Hyg., 1994; 88:670), pyelonephritis (Becker KL, et al., "The hyperprocalcitonemia of severe infections," Endocrine Society, Washington, DC, June 14-17, 1995), etc.), serum ProCT levels as high as 200 ng/mL were reported. The SIRS which is secondary to pancreatitis (Becker KL, et al., Endocrine Society, Washington, DC, June 1995; and White J., et al., Pancreas Club, San Francisco, CA May 19, 1996), burns (O'Neill W., et al., J. Burn Care Rehab., 1992; 13:605; and Becker K., et al. Anat. Rec., 1993; 236:136), and heat stroke (Nylen ES, et al., Crit. Care Med. (In Press), 1997), also were found to manifest high serum levels of CT precursors (i.e., ProCT and/or its components).

In severe burns, greatly elevated levels of ProCT and/or its components were found, which correlated positively with mortality; these levels had considerable prognostic utility, sufficient to influence the type and aggressivity of therapy (Nylen E, et al., Horm. Metab. Res., 1992; 24:439; and Nylen ES, et al., Respir. Med., 1995; 89:41). It has since been determined that the high levels of CT precursor forms found in

these patients consist mostly of ProCT, nProCT and the CT:CCP-I peptide, with mature CT being either normal or minimally elevated.

Interestingly, a linkage between endotoxin, inflammatory cytokines, and hyperprocalcitonemia was demonstrated by an experiment in which injection of endotoxin from *E. coli* bacteria into volunteers produced fever, chills and myalgia; serum TNF α increased to peak serum levels at 1-1/2 hr, and IL-6 peaked at 6 hr (Dandona P, et al., J. Clin. Endocrinol. Metab., 1994; 79:1605). Both of these cytokines then gradually normalized. Serum ProCT, initially undetectable, peaked at 6 hours (4.5 ng/mL), and thereafter maintained a plateau until at least 24 hr. Mature CT remained undetectable.

The conventional treatment of SIRS/sepsis varies according to the initiating cause (e.g., burns, infection, multitrauma, pancreatitis). Therapy may include cardiovascular support such as fluids and adrenergic agents, antibiotics, corticosteroids, respiratory assistance, oxygen, renal dialysis, etc. In addition, antibodies or antagonists to cytokines or endotoxin have been evaluated (Zeigler, EJ, et al., New Engl. J. Med., 1991; 324:429; and Christman, JW, et al., Crit. Care Med., 1995; 25:955). However, in spite of these therapies, SIRS and the sepsis syndromes continue to have an extremely high morbidity and mortality (Natanson, C, et al., Ann Int Med, 1994; 120:771; Suffredini, AF, Crit. Care Med., 1994; 22:512; and Fisher, CJ, et al., New Eng. J. Med.,

1996; 334:1697). Thus, there is no very effective method for preventing and/or treating SIRS, and there remains a very compelling need for alternative methods for preventing and/or treating SIRS/sepsis. There also remains a need for pharmaceutical compositions useful for preventing and/or treating SIRS/sepsis.

SUMMARY OF THE INVENTION

Accordingly, it is one object of the present invention to provide a novel method for preventing SIRS/sepsis.

It is another object of the present invention to provide a novel method for treating SIRS/sepsis.

It is another object of the present invention to provide novel compositions useful for preventing SIRS/sepsis.

It is another object of the present invention to provide novel compositions useful for treating SIRS/sepsis.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that administration, to a mammal, of an effective amount of an antibody specific for a component of procalcitonin, is effective for the prevention and/or treatment of SIRS/sepsis.

BRIEF DESCRIPTION OF THE DRAWINGS

A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the

following detailed description when considered in connection with the accompanying drawings, wherein:

Figure 1 illustrates the ability of an anti-ProCT antibody (in this case an antiserum to mature CT) to prevent death in hamsters with *E. coli* peritonitis;

Figure 2 shows the ability of anti-CT antibody to reduce the mortality rate in hamsters when administered after the induction of *E. coli* peritonitis with five intraperitoneal injections at 1, 3, 6, 12, and 24 hours after the induction of peritonitis; and

Figure 3 shows the ability of anti-CT antibody to reduce the mortality rate in hamsters when administered after the induction of *E. coli* peritonitis with two intraperitoneal injections at 3 and 24 hours after the induction of peritonitis.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Thus, in a first embodiment, the present invention provides a method for preventing and/or treating SIRS/sepsis by administering, to a human or other mammal in need thereof, an effective amount of an antibody reactive to procalcitonin or its component(s) (hereinafter referred to as anti-procalcitonin). In the context of the present invention, the term SIRS includes both sepsis and systemic inflammation from non-infectious sources. Thus, the present method is effective for the prevention and/or treatment of SIRS/sepsis resulting from bacterial, viral, parasitic, rickettsial, or fungal

infection, and/or SIRS/sepsis resulting from any of a number of non-infectious causes (e.g., burns, pancreatitis, multi-trauma, severe surgical trauma, transplant rejection, marked autoimmune reaction, ischemia reperfusion, transfusion reaction, heat stroke). In the context of the present invention, the term prevention also means the amelioration of the severity of SIRS/sepsis by administration prior to the onset of SIRS/sepsis.

Human calcitonin (CT) is a single-chain peptide consisting of 32 amino acid residues. The free, active, so-called "mature" CT hormone has an amidated proline at its carboxyl-terminus (Eipper BA, et al., Annu. Neurosci., 1992; 15:57). The polypeptide precursor of CT is pre-procalcitonin (Pre-ProCT), containing 141 amino acid residues. The CALC-I gene encodes the information for its primary structure (Becker KL, et al., in Principles and Practice of Endocrinology and Metabolism, 2nd ed., Becker KL, Ed., JB Lippincott Co., Philadelphia, 1995, p. 474). The 25 amino acid leader sequence assists the transport of the ribosomal precursor molecule into the cisternae of the rough endoplasmic reticulum; it is cleaved early in post-translational processing by a signal peptidase. The resultant prohormone, procalcitonin (ProCT; also termed PAN-116) consists of 116 amino acid residues (LeMoulec JM, et al., FEBS Lett., 1984; 167:93). At the amino terminus portion of ProCT, there is a 57-amino acid peptide called nProCT (also termed PAS-57). Immature CT is centrally placed within CT; it consists of 33 amino acid residues, including a carboxyl terminal glycine.

The final 21-amino acid residues comprise the CT carboxyl terminal peptide-I (also termed PDN-21 or katacalcin). There also is an alternative form, present in much lower concentrations, termed CCP-II.

The biosynthetic secretory pathway for CT involves a complex series of modifications which eventuates in the final exocytosis of the mature secretory product. Topographically, in the neuroendocrine secretion of CT, the highly organized traffic from the endoplasmic reticulum passes through the Golgi apparatus, dense-core secretory vesicles, and, eventually the cell surface. This regulated secretory pathway for a CT molecule that is comprised mostly of the mature, bioactive form, differs from the constitutional, unregulated secretory pathway by which, in all likelihood, mostly ProCT is secreted (Burgess TC, et al., Annu. Rev. Cell Biol., 1987; 243; Mostov KE, Histol. Histopathol., 1995; 10:423; and Rothman JE, et al., FASEB J., 1990; 4:1460). Although the mechanism by which the larger precursor, ProCT, is serially processed has not been entirely elucidated, the general outline is known. Proteolytic cleavages occur in the trans-Golgi and the secretory vesicles. The amidation process, which converts immature CT to its more active free mature form, probably occurs within the secretory vesicles (Steiner DF, et al., J. Biol. Chem., 1992; 267:23435). In the regulated pathway, as occurs in neuroendocrine cells, these dense-core vesicles are destined to serve as storage repositories for later secretion; without the appropriate

external stimulus, they have relatively long half-lives. Ultimately, in response to the appropriate signal at the plasma membrane, there is a brief increase of concentration of cytosol free Ca^{2+} that induces exocytosis. In CT-secreting NE cells, the vesicles of the regulated pathway contain, in addition to mature CT, the nProCT, CCP-I, CT:CCP-I (Treilhou-Lahille F, et al., Biology of the Cell, 1986; 57:221), and perhaps CCP-II and CT:CCP-II peptides; most of these components are found, in very low concentrations, in the sera of normal persons (Becker, KL, et al., Procalcitonin and its constituent peptides circulate in normal persons, 15th Joint Meeting of British Endocrine Societies, Dublin Ireland, March 26, 1996).

The measurement of serum immunoreactive CT (iCT) has long been employed to detect and follow the course of the neoplasm of the thyroid C-cells, medullary thyroid cancer (MTC) (Becker KL, et al., Acta Endocrinol., 1978; 89:89; and Becker KL et al., Surg. Gynecol. Obstet., 1982; 154:897). Current immunoassays are fashioned so as to detect predominantly or exclusively the free, amidated, mature CT (Guilloteau D, et al., J. Clin. Endocrinol. Metab., 1990; 71:1064; Motté P, et al., Clin. Chim. Acta., 1988; 174:35; Seth R, et al., Horm. Metab. Res. Suppl., 1989; 21:3; and Weissel M, et al., Acta Endocrinol., 1991; 124:540); the most specific two-antisera capture assays used for this purpose probably do not detect ProCT or any of its other components. However, the use of region-specific antisera and separatory techniques has demonstrated that in addition to secreting considerable

amounts of mature CT, MTC also secretes large amounts of ProCT and its components. In addition, two neoplasms of the lung, the malignant small cell lung cancer and the more benign bronchial carcinoid, which are putative tumors of CT-containing pulmonary neuroendocrine cells, often secrete immunoreactive CT (Becker KL, et al., in Comparative Respiratory-Tract Carcinogenesis, Reznick-Schuller H, Ed., CRC Press, Boca Raton, FL, 1983; p. 161; and Becker KL, et al., Biochem. Pharmacol., 1985; 34:155). A similar phenomenon of immunoreactive CT secretion occurs in some seemingly non-neuroendocrine tumors.

There is no particular limitation on the anti-procalcitonin antibody which can be used in the present invention. Furthermore, the anti-procalcitonin may be either a polyclonal antibody or monoclonal antibody, or a mixture thereof. The antibody may be to the intact ProCT or any of its components, i.e., the immature CT, mature CT, CCP-I, CCP-II, nProCT, or to any other fragments or amino acid sequence(s) of the known ProCT molecule, so long as it is able to bind to and neutralize procalcitonin. In the case of nonhuman mammals, the antibody may be to any component, fragment, or amino acid sequence of the respective procalcitonin structure of that mammal. The antibody also may be to amino acid or other chemical modifications of the human or mammalian molecular structure of ProCT or its component peptides or amino acid sequences.

Good results have been achieved using polyclonal antibodies. In another preferred embodiment, the anti-

procalcitonin is a monoclonal antibody or a mixture of two or more monoclonal antibodies, or a mixture of monoclonal plus polyclonal antibodies. The suitability of the monoclonal or polyclonal antibody(ies) produced for use in the present invention may easily be determined *in vitro* (binding to ProCT or ProCT-component peptides). It may additionally be evaluated by means of the hamster model as described in the Examples below.

The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.

Methods for producing polyclonal anti-polypeptide antibodies are well-known in the art. See U.S. Patent No. 4,493,795 to Nestor et al. A monoclonal antibody, typically containing Fab and/or F(ab'), portions of useful antibody molecules, can be prepared using the hybridoma technology described in *Antibodies - A Laboratory Manual*, Harlow and Lane, eds., Cold Spring Harbor Laboratory, New York (1988), which is incorporated herein by reference. Briefly, to form the hybridoma from which the monoclonal antibody composition is produced, a myeloma or other self-perpetuating cell line is

fused with lymphocytes obtained from the spleen of a mammal hyperimmunized with procalcitonin, calcitonin, etc.

Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 6000. Fused hybrids are selected by their sensitivity to HAT. Hybridomas producing a monoclonal antibody useful in practicing this invention are identified by their ability to produce antibodies which immunoreact with procalcitonin.

A monoclonal antibody useful in practicing the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate antigen specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well-known techniques.

Media useful for the preparation of these compositions are both well-known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virol. 8:396 (1959)) supplemented with 4.5 gm/l glucose, 20 mm glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

Methods for producing monoclonal antibodies to such peptides as procalcitonin or its components are also well-known in the art. See Niman et al., *Proc. Natl. Acad. Sci. USA*, 80:4949-4953 (1983). Typically, the present procalcitonin or a peptide analog is used either alone or conjugated to an immunogenic carrier, as the immunogen in the before described procedure for producing anti-procalcitonin monoclonal antibodies. The hybridomas are screened for the ability to produce an antibody that immunoreacts with the procalcitonin peptide analog.

The anti-procalcitonin may be administered either intravenously, subcutaneously, intramuscularly, intrapleurally, intraperitoneally, orally, and/or rectally. When administered intravenously, the anti-procalcitonin is preferably in the form of a sterile saline, or other physiologic electrolyte solution. Similar diluents may be used for the other routes. Oral or rectal administration may require an adjuvant which augments absorption.

Although the exact dosage of anti-procalcitonin to be administered will depend on the patient's clinical condition and/or the observed increases in levels of serum procalcitonin (1 to 500 ng/mL), or of nProCT (500 to 250,000 pg/mL). The anti-procalcitonin is suitably administered in an amount which is sufficient to bind, *in vitro*, 0.4 to 100 nmol of procalcitonin and/or its component peptides per kg of body weight of the patient, commonly 10 to 100 nmol of procalcitonin and/or its component peptides per kg of body

weight. An occasional case may require a dose higher than that which is sufficient to bind, *in vitro*, 100 nmol of procalcitonin per kg of body weight of the patient.

The anti-procalcitonin may be administered in a single dose or given in 2 to 10 divided doses administered during the 24 hour period immediately subsequent to the clinical suspicion of imminent SIRS/sepsis or an infection or other illness or condition suspected or feared to eventuate in SIRS/sepsis. On 2-4 subsequent days, repeat doses may be administered once or in 2-4 divided doses, equivalent to a total daily dose of 25-100% of the total daily dose given on day one, dependent on the patient's clinical response. As therapy of diagnosed SIRS/sepsis, the anti-procalcitonin is administered in a similar manner. However, repeat dosing may be needed for many days if the patient is extremely ill and has clinical complications. Either as prevention or as therapy, relative to the intravenous route of injection, dosages for other routes would be 2X for intrapleural and intraperitoneal, 4X for intramuscular, 5X for subcutaneous, and 8X for oral and rectal.

Good results have been achieved in our laboratory model by the intraperitoneal administration of anti-procalcitonin sufficient to bind 9 to 10.5 nmol/kg procalcitonin in 2 to 5 divided doses during the 24 hr following the beginning of sepsis, subsequently administering booster doses as needed.

As noted above, the present method is useful for preventing and/or treating SIRS/sepsis. The administration of

anti-procalcitonin may be commenced in cases of suspected or early stages of infection or SIRS, or after the onset of overt SIRS/sepsis. Furthermore, the onset may be determined by fulfillment of the criteria of the definition of SIRS. Other findings, which may or may not be present, may include the presence of bacteria in the blood, increased levels of procalcitonin or its components in the blood; increased serum, salivary or urine levels of cytokines; or increased serum levels of C-reactive protein, or serum endotoxin, or serum or urine neopterin. Alternatively, the anti-procalcitonin administration may be commenced prior to the actual onset of SIRS/sepsis to a patient or subject who is at risk for developing sepsis or severe systemic inflammation (e.g., only one of the prior-referenced criteria of SIRS, or after a burn, trauma, extensive surgery, transfusion reaction, graft/organ rejection, heat stroke, heat exhaustion, pancreatitis, or a known or suspected infection).

Subjects who are at risk of developing SIRS or sepsis include newborn babies and infants, the elderly, the immunocompromised patient (e.g., a patient receiving corticosteroids or chemotherapy, a patient with the acquired immunodeficiency syndrome), or, as mentioned above, in persons with burns, infection, heat stroke, pancreatitis, severe autoimmune disease, transfusion reaction, extensive surgery, graft/organ rejection, or pancreatitis.

When used therapeutically, the anti-procalcitonin antibody should be administered as soon as a patient with the onset of infection or SIRS/sepsis has been identified.

Subsequent doses may be administered once to twice daily until the patient shows clinical indications of recovery, and/or a markedly decreased blood level of procalcitonin or its components, and/or a decrease of blood, urine or salivary levels of cytokines, of C-reactive protein, of neopterin, or of endotoxin. Based upon the clinical and/or laboratory findings (such as leukocyte count, cytokine levels, ProCT levels and/or ProCT component levels), doses may be administered more frequently or less frequently.

When used preventively, as soon as a patient with the aforementioned risks has been identified, he or she should receive the anti-procalcitonin antibody. It should be repeated once or twice daily until clinical and aforementioned laboratory criteria indicate that the patient is no longer at risk of developing SIRS/sepsis. Based upon the clinical and/or the serum levels of ProCT or its components, and/or the prior-mentioned clinical and laboratory parameters, doses may be administered more frequently or less frequently.

When used either preventively or therapeutically, the anti-procalcitonin antibody may be administered intravenously, subcutaneously, intramuscularly, intraperitoneally, intrapleurally, orally, rectally, or by combinations thereof. The administration may be intermittent or continuous (e.g., continuous intravenous infusion).

When used either preventively or therapeutically, the anti-procalcitonin antibody may be administered with other agents such as corticosteroids, thyroid hormone, and/or antibiotics, and/or cytokine antagonists and/or anti-cytokine

antibodies, and/or endotoxin antagonists or anti-endotoxin antibodies; and/or may be administered with any other therapy known or suspected to be beneficial to treat SIRS/sepsis or to avert its onset.

Although not intending to be bound by any theory or mechanism, the present inventors provide the following comments on the phenomena underlying the present invention.

There is increasing evidence for biological activity of some prohormones and their components in addition to the classical mature hormone to which they give rise. Prior to the present invention, the impact of hyperprocalcitonemia on the patient with infection or SIRS/sepsis was unknown. SIRS/sepsis is commonly associated with multiple symptomatic, clinical, and metabolic manifestations and some of them (such as hyperglycemia and hypocalcemia), may, perhaps, be attributable to the effects of procalcitonin and/or its components.

HPLC on sera of SIRS patients has been performed to determine whether the hypersecretion of ProCT in SIRS is a phenomenon common to other prohormones as well: increased serum levels of ProCGRP or mature CGRP were not detected. Also, since endotoxin and cytokines can acutely stimulate the hypothalamic-pituitary-adrenal axis (Mastorakos G, et al., *J. Clin. Endocrinol. Metab.*, 1994; 79:934), serum proopiomelanocortin (POMC) was measured (two-antibody sandwich technique), and was normal, as was serum ACTH.

The cause of the hypersynthesis of ProCT is not apparent. The immediate signal may be a factor, perhaps primarily or

secondarily due to a cytokine, which induces an intranuclear message. Alternatively, the CT gene may contain a regulatory region common to inflammatory mediators (Schutze, S, et al., Immunobiology, 1995; 193:193). One might postulate a scenario in which a greatly stimulated hypersynthesis of ProCT produced by CT-secreting neuroendocrine cells overwhelms their endoproteolytic machinery. If neuroendocrine tissue is the source, such an extraordinarily augmented and ongoing hypersecretion of ProCT and its components in the face of a normal serum level of mature CT suggests not only hypersynthesis, but also a marked shift to the constitutive pathway of secretion, resulting in an incomplete processing of precursors.

The constitutive secretory pathway is present in all cells; here, the vesicles which bud off from the trans-Golgi are much less dense than those of the regulated pathway, and migrate rapidly to the plasma membrane. Hence, in contrast to the slow transit-time of the dense vesicles of the regulated system, which await periodic stimuli for exocytosis, the constitutive pathway vesicles are involved in a non-storing, bulk-flow continuous secretion of newly synthesized peptide(s); the vesicles fuse continuously with the plasma membrane, and the extrusion of their hormonal material may be calcium independent.

If the source of the ProCT is neuroendocrine cells, there may be either an increased transcription of its gene or, post-transcriptionally, an increased stability of its mRNA. If it is regulated at the transcriptional level, it may be acting on

possible enhancer-like sequences in the ProCT gene promoter. In either case, the major factor determining the exceptional predominance of prohormonal forms would likely be the choice of the trans-Golgi to route to the constitutive pathway, thus bypassing much of the enzymatic processing (Burgess TC, et al., Annu. Rev. Cell Biol., 1987; 243; and Rothman JE, et al., FASEB J., 1990; 4:1460).

Experimentally, such a shift to constitutional secretion has been shown to occur by the induction of dysfunctional prohormone convertase enzymes, by the loss of Golgi recognition molecules, by diminished intracellular calcium, by alkalinization of cytoplasmic organelles, or by depolarization of the plasma membrane. In this regard, some cytokines may indeed be able to induce constitutive secretion due to membrane depolarization (Mostov KE, Histol. Histopathol., 1995; 10:423; and Madara JL, et al., J. Clin. Invest., 1989; 83:724).

However, it is quite possible that these enormous serum levels of ProCT in infection or SIRS/sepsis do not originate from neuroendocrine cells, either exclusively, or perhaps, at all. In this respect, hyperprocalcitonemia of SIRS/sepsis can occur in the absence of the thyroid gland, a structure that produces an appreciable amount of the serum immunoreactive CT of normal persons (Assicot M, et al., Lancet, 1993; 341:515). Also, it is well known that some hormonal peptides, which are normally secreted by neuroendocrine cells, are contained within other presumably non-neuroendocrine cells, albeit at low levels (Krieger DT, Clin. Res., 1983; 3:342; and LeRoith

D, et al., Adv. Metabolic Disorders, 1983; 10:303). Non-neuroendocrine cells presumably possess cell-type regulatory mechanisms limiting expression of ProCT mRNA. It is conceivable that this mechanism is deregulated by unusually high levels of a SIRS-related secretagogue. Stimulation of synthesis in such non-neuroendocrine cells would preferentially induce ProCT secretion because they lack the enzymes for complete prohormonal processing.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

Materials and Methods:

Animals: Golden Syrian Hamsters - 100g were housed in a controlled environment and were exposed to 12 hour, light-dark cycles. The animals were given unrestricted access to water and standard rodent chow. This study was approved by the Institutional Animal Care and Use Committee at the Veterans Affairs Medical Center, Washington, D.C.

Bacteria: *Escherichia coli* (O18:K1:H7) was obtained from Dr. Alan S. Cross, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Washington, D.C. It was grown in 100 ml of LB Broth (Fischer Scientific) at 37°C in a shaker water bath to log phase and stored in 250 µl aliquots at -70°C until use.

Intra-abdominal pellets: *Escherichia coli* were prepared by growing a frozen aliquot of bacteria to log phase, quantitating the colonies via spectrophotometry, diluting the stock to 1.0×10^3 cfu/ml and serially plating appropriate dilutions for confirmation. Pellets for intra-abdominal challenge were made by adding 0.5 ml of an *Escherichia coli* suspension to 0.5 ml of sterile molten agar at 50°C and allowing the mixture to solidify at room temperature in an 8 mm plastic imbedding mold. The final number of viable colony forming units of bacteria in each infected pellet was 5.0×10^5 .

Induction of Peritonitis: The method for inducing peritonitis has been reported: (Dunne, JR, et al., J. Surg. Res., 1996; 61:348; and Steinwald, P, et al., Intl. Congress Endocrinology, San Francisco, CA, June 1996). Bacterial peritonitis was then produced by intraperitoneal implantation of the infected agar pellets. After anesthetizing each animal with 50 mg/kg pentobarbital, i.p. and prepping the abdomen with 70% alcohol, the peritoneal cavity was opened via a midline incision. An infected agar pellet was placed in the right lower quadrant and the incision was closed in two layers with a running 4-0 nylon suture. Each animal was given a single, intramuscular injection of ceftriaxone (14.3 mg/kg, Roche, Nutley, NJ) and was placed in a separate cage to recover from anesthesia. Water and rat chow were again provided *ad libitum*.

Antibodies: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride, 8 mg, was used to couple 4 mg synthetic human calcitonin (Organon), to 16 mg hemocyanin (keyhole limpet, Calbiochem, La Jolla, CA). The dialyzed conjugate, 17 mg, was suspended in 10 mL of 0.154 M NaCl. Initially, and at 2 weeks, a 25 kg goat received multiple intradermal injections on its back of an emulsion consisting of 1 mL of the conjugate suspension and 1 mL complete Freund's adjuvant. The goat also received a subcutaneous injection of 0.5 mL pertussis vaccine. Antibody to calcitonin/procalcitonin was detectable within one month of the first injection. Subsequent booster injections (multiple intradermal sites on the back), given at monthly intervals, consisted of an emulsion containing 0.5 mL of the conjugate suspension and 0.5 mL of incomplete Freund's Adjuvant (lanolin). Subcutaneous booster injections of 0.5 mL pertussis vaccine were also administered. The booster injections were discontinued after 5 months and resumed when the titer began to decline at 9 months. The antiserum bleedings chosen for neutralization studies (bleedings 12-26) were collected between 5 and 20 months. The estimated titers of these antisera, which were multiregion specific for calcitonin, ranged from 1:500,000 to 1:2,000,000.

Example 1. Prevention of Mortality.

Peritonitis was induced in 32 Golden Syrian Hamsters as described in the Materials and Methods section. At 0 and 24 hr, the experimental animals (n=16) received intraperitoneal

injections of the anti-CT multiregion specific goat polyclonal antiserum (titer of 1:1,000000), capable of detecting hamster mature CT and ProCT in radioimmunoassays, and prepared as described in the Materials and Methods section. Controls (n=16) received non-immune goat serum. There was no mortality in the experimental group in 72 hours despite 45% mortality in the control group ($p<0.004$). The results are presented graphically in Figure 1. The solid bars represent the cumulative mortality of the control group of hamsters which did not receive antibodies reactive to procalcitonin and the open bars represent the cumulative mortality of the experimental group which received antibodies reactive to procalcitonin. In view of the remarkable effectiveness of antiserum treatment, the experimental group was followed for another 60 hr, during which time only one of the treatment animals died. Furthermore, mortality was also reduced when the initial intraperitoneal antiserum injection was delayed until 3 hr after *E. coli* implantation.

The statistical significance of the data at each time is shown in the following table:

Time (hr)	p <
12	0.448
24	0.011
48	0.004
72	0.004

Example 2. Therapy of Sepsis.

The experiment described in Example 1 was repeated with the exception that the experimental animals (n=12) received intraperitoneal injections of the anti-CT multiregion specific goat polyclonal antiserum (titer of 1:1,000,000) at 1, 3, 6, 12, and 24 hours after the induction of peritonitis. The control animals (n=12) received no anti-CT antiserum. The results are shown in Figure 2. The statistical significance of the data at each time is shown in the following table:

Time (hr)	p <
12	1
24	0.342
36	0.342
48	0.317
60	0.430
72	0.245

Example 3. Therapy of Sepsis.

The experiment described in Example 1 was repeated with the exception that the experimental animals (n=16) received intraperitoneal injections of the anti-CT multiregion specific goat polyclonal antiserum (titer of 1:1,000,000) at 3 and 24 hours after the induction of peritonitis. The control animals (n=16) received no anti-CT antiserum. The results are shown in Figure 3. The statistical significance of the data at each time is shown in the following table:

Time (hr)	p <
12	1
24	0.42
36	0.113
48	0.222
60	0.222
72	0.481

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

CLAIMS:

1. A method for treating and/or preventing systemic inflammatory response syndrome including sepsis (SIRS/sepsis), comprising administering, to a mammal in need thereof, an effective amount of an antibody reactive to procalcitonin and/or one or more of its components.
2. The method of Claim 1, wherein said antibody is a polyclonal antibody.
3. The method of Claim 1, wherein said antibody is a monoclonal antibody.
4. The method of Claim 1, wherein said antibody comprises of multiple monoclonal, multiple polyclonal antibodies, or a combination of monoclonal and polyclonal antibodies.
5. The method of Claim 1, wherein said mammal is a human.
6. The method of Claim 1, wherein said mammal is selected from the group consisting of cats, dogs, cows, horses, and pigs.
7. The method of Claim 1, wherein said antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, within the pleural cavity, orally or rectally.
8. The method of Claim 1, wherein said antibody is administered in an amount sufficient to bind, in vitro, 0.4 to 100 nmol/kg of procalcitonin and/or its component peptides.
9. The method of Claim 1, wherein said antibody is administered in an amount sufficient to bind, in vivo, 0.4 to

100 nmol/kg of procalcitonin and/or its component peptides.

10. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis induced by bacterial infection or presumed bacterial infection.

11. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from a burn.

12. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from pancreatitis.

13. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from trauma.

14. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from extensive surgery.

15. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from heat exhaustion or heat stroke.

16. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from pneumonia/pneumonitis or other bacterial infection.

17. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from a virus or retrovirus infection.

18. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from parasitic infection.

19. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from spirochetal infection.

20. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from fungal infection.

21. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from rickettsial infection.

22. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from transfusion reaction.

23. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from graft/organ rejection.

24. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from severe autoimmunity reaction.

25. The method of Claim 1, wherein said mammal is suffering from SIRS/sepsis resulting from toxic shock syndrome.

26. The method of Claim 1, wherein said mammal does not have SIRS/sepsis and said mammal is suffering from a condition selected from the group consisting of severe infection, aspiration pneumonitis, toxic shock syndrome, trauma, extensive surgery, burns, heat exhaustion, heat stroke, pancreatitis, transfusion reaction, graft/organ rejection, marked autoimmune reaction, and ischemia reperfusion injury.

27. The use of an antibody reactive to procalcitonin and/or one or more of its components for the manufacture of a medicament for the treatment and/or prevention of systemic inflammatory response syndrome including sepsis (SIRS/sepsis) in a mammal.

28. The use of Claim 27, wherein said antibody is a

polyclonal antibody.

29. The use of Claim 27, wherein said antibody is a monoclonal antibody.

30. The use of Claim 27, wherein said antibody comprises of multiple monoclonal, multiple polyclonal antibodies, or a combination of monoclonal and polyclonal antibodies.

31. The use of Claim 27, wherein said mammal is a human.

32. The use of Claim 27, wherein said mammal is selected from the group consisting of cats, dogs, cows, horses, and pigs.

33. The use of Claim 27, wherein said antibody is administered to said mammal intravenously, subcutaneously, intramuscularly, intraperitoneally, within the pleural cavity, orally or rectally.

34. The use of Claim 27, wherein said antibody is administered to said mammal in an amount sufficient to bind, in vitro, 0.4 to 100 nmol/kg of procalcitonin and/or its component peptides.

35. The use of Claim 27, wherein said antibody is administered to said mammal in an amount sufficient to bind, in vivo, 0.4 to 100 nmol/kg of procalcitonin and/or its component peptides.

36. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis induced by bacterial infection or presumed bacterial infection.

37. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from a burn.

38. The use of Claim 27, wherein said mammal is

suffering from SIRS/sepsis resulting from pancreatitis.

39. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from trauma.

40. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from extensive surgery.

41. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from heat exhaustion or heat stroke.

42. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from pneumonia/pneumonitis or other bacterial infection.

43. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from a virus or retrovirus infection.

44. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from parasitic infection.

45. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from spirochetal infection.

46. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from fungal infection.

47. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from rickettsial infection.

48. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from transfusion reaction.

49. The use of Claim 27, wherein said mammal is

suffering from SIRS/sepsis resulting from graft/organ rejection.

50. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from severe autoimmunity reaction.

51. The use of Claim 27, wherein said mammal is suffering from SIRS/sepsis resulting from toxic shock syndrome.

52. The use of Claim 27, wherein said mammal does not have SIRS/sepsis and said mammal is suffering from a condition selected from the group consisting of severe infection, aspiration pneumonitis, toxic shock syndrome, trauma, extensive surgery, burns, heat exhaustion, heat stroke, pancreatitis, transfusion reaction, graft/organ rejection, marked autoimmune reaction, and ischemia reperfusion injury.

53. A pharmaceutical composition for treating and/or preventing systemic inflammatory response syndrome including sepsis (SIRS/sepsis) in a mammal, comprising an effective amount of an antibody reactive to procalcitonin and/or one or more of its components.

54. The pharmaceutical composition of Claim 53, wherein said antibody is a polyclonal antibody.

55. The pharmaceutical composition of Claim 53, wherein said antibody is a monoclonal antibody.

56. The pharmaceutical composition of Claim 53, wherein said antibody comprises of multiple monoclonal, multiple polyclonal antibodies, or a combination of monoclonal and polyclonal antibodies.

57. The pharmaceutical composition of Claim 53, wherein said mammal is a human.

58. The pharmaceutical composition of Claim 53, wherein said mammal is selected from the group consisting of cats, dogs, cows, horses, and pigs.

59. The pharmaceutical composition of Claim 53, which is administered to said mammal intravenously, subcutaneously, intramuscularly, intraperitoneally, within the pleural cavity, orally or rectally.

60. The pharmaceutical composition of Claim 53, which is administered to said mammal in an amount sufficient to bind, *in vitro*, 0.4 to 100 nmol/kg of procalcitonin and/or its component peptides.

61. The pharmaceutical composition of Claim 53, which is administered to said mammal in an amount sufficient to bind, *in vivo*, 0.4 to 100 nmol/kg of procalcitonin and/or its component peptides.

62. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis induced by bacterial infection or presumed bacterial infection.

63. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from a burn.

64. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from pancreatitis.

65. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from

trauma.

66. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from extensive surgery.

67. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from heat exhaustion or heat stroke.

68. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from pneumonia/pneumonitis or other bacterial infection.

69. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from a virus or retrovirus infection.

70. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from parasitic infection.

71. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from spirochetal infection.

72. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from fungal infection.

73. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from rickettsial infection.

74. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from transfusion reaction.

75. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from graft/organ rejection.

76. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from severe autoimmunity reaction.

77. The pharmaceutical composition of Claim 53, wherein said mammal is suffering from SIRS/sepsis resulting from toxic shock syndrome.

78. The pharmaceutical composition of Claim 53, wherein said mammal does not have SIRS/sepsis and said mammal is suffering from a condition selected from the group consisting of severe infection, aspiration pneumonitis, toxic shock syndrome, trauma, extensive surgery, burns, heat exhaustion, heat stroke, pancreatitis, transfusion reaction, graft/organ rejection, marked autoimmune reaction, and ischemia reperfusion injury.


Figure 1.



Figure 2.

Figure 3.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/00985

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) A61K 39/395

US CL 424/130.1, 139.1, 141.1, 145.1, 158.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 139.1, 141.1, 145.1, 158.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS and DIALOG (files 5, 155, 351, 357, 358) search terms: calcitonin, procalcitonin, antibody, monoclonal, polyclonal, sepsis, systemic inflammatory response, SIRS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	QUEZADO et al. New strategies for combatting sepsis: the magic bullets missed the mark...but the search continues. TIBTECH. February 1995, Vol. 13, pages 56-63.	1-26, 53-78
X, P	US 5,639,617 A (BOHUON) 17 June 1997, col. 3-4 and claims.	53-78
X	US 5,277,393 A (SAKAKIBARA et al) 07 July 1981, col. 26, lines 30-45.	53-78
X	US 5,330,909 A (YAMASHITA et al) 19 July 1994, abstract and claims.	53-78

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* "A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
* "O" document referring to an oral disclosure, use, exhibition or other means		
* "P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

Date of mailing of the international search report

20 MARCH 1998

26 MAY 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized officer *Marianne P. Allen*
MARIANNE P. ALLEN
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US98/00985**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 27-52
because they relate to subject matter not required to be searched by this Authority, namely:

These claims are directed to a use of an antibody without setting forth any steps involved in the process which is not a proper process claim under 35 USC 101.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)